PT3478712T - Anticorpos anti-péptido beta amiloide n3pglu e suas utilizações - Google Patents

Anticorpos anti-péptido beta amiloide n3pglu e suas utilizações

Info

Publication number
PT3478712T
PT3478712T PT177368412T PT17736841T PT3478712T PT 3478712 T PT3478712 T PT 3478712T PT 177368412 T PT177368412 T PT 177368412T PT 17736841 T PT17736841 T PT 17736841T PT 3478712 T PT3478712 T PT 3478712T
Authority
PT
Portugal
Prior art keywords
amyloid beta
beta peptide
peptide antibodies
n3pglu amyloid
n3pglu
Prior art date
Application number
PT177368412T
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT3478712T publication Critical patent/PT3478712T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT177368412T 2016-07-01 2017-06-23 Anticorpos anti-péptido beta amiloide n3pglu e suas utilizações PT3478712T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662357579P 2016-07-01 2016-07-01

Publications (1)

Publication Number Publication Date
PT3478712T true PT3478712T (pt) 2023-08-21

Family

ID=59295341

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177368412T PT3478712T (pt) 2016-07-01 2017-06-23 Anticorpos anti-péptido beta amiloide n3pglu e suas utilizações

Country Status (28)

Country Link
US (2) US11312763B2 (pt)
EP (2) EP4272828A3 (pt)
JP (4) JP7165588B2 (pt)
KR (3) KR20210024213A (pt)
CN (3) CN114887054A (pt)
AU (1) AU2017291414B2 (pt)
BR (1) BR112018073843A2 (pt)
CA (1) CA3029550C (pt)
DK (1) DK3478712T3 (pt)
EA (1) EA201892690A1 (pt)
ES (1) ES2958508T3 (pt)
FI (1) FI3478712T3 (pt)
HR (1) HRP20230861T1 (pt)
HU (1) HUE062980T2 (pt)
IL (1) IL263788B1 (pt)
LT (1) LT3478712T (pt)
MA (1) MA45543B1 (pt)
MD (1) MD3478712T2 (pt)
MX (2) MX2018016066A (pt)
PL (1) PL3478712T3 (pt)
PT (1) PT3478712T (pt)
RS (1) RS64386B1 (pt)
SG (1) SG11201810371XA (pt)
SI (1) SI3478712T1 (pt)
TW (2) TWI735600B (pt)
UA (1) UA127101C2 (pt)
WO (1) WO2018005282A1 (pt)
ZA (1) ZA201807633B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EP3521308B1 (en) * 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
WO2019169448A1 (en) * 2018-03-09 2019-09-12 St Vincent's Institute Of Medical Research Multi-specific antibodies
JP2021532126A (ja) * 2018-07-24 2021-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病の治療及び予防方法
CN111184725B (zh) * 2020-02-27 2020-12-01 慈溪市人民医院医疗健康集团(慈溪市人民医院) 一种防治脑梗塞的药物制剂及其制备方法
EP4274611A1 (en) * 2021-01-11 2023-11-15 Eli Lilly and Company Anti-n3pglu amyloid beta antibodies and uses thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023076970A1 (en) * 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
TW202336034A (zh) * 2021-10-29 2023-09-16 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
WO2023146818A2 (en) * 2022-01-26 2023-08-03 T3D Therapeutics, Inc. Methods of treating amyloid related brain disorders using novel compounds and antibodies
WO2023150483A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1397539A (en) * 1920-01-14 1921-11-22 Odell Risdon Moore Egg-carton
KR100767146B1 (ko) 2000-02-24 2007-10-15 워싱톤 유니버시티 Aβ 펩티드를 격리시키는 인간화 항체
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
KR101068289B1 (ko) 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
UY30003A1 (es) 2005-12-12 2007-08-31 Hoffmann La Roche Anticuerpos glicosilados en la region variable
NZ567888A (en) 2006-03-23 2010-08-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
ES2615454T3 (es) 2007-01-18 2017-06-07 Eli Lilly And Company Fab pegilado contra el amiloide beta
JP5889529B2 (ja) * 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
EP2310032A2 (en) 2008-06-12 2011-04-20 Affiris AG Compounds for treating symptoms associated with parkinson's disease
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
EA028427B1 (ru) 2008-07-21 2017-11-30 Пробиодруг Аг АНТИТЕЛО, СВЯЗЫВАЮЩЕЕСЯ С Aβ-ПЕПТИДАМИ ИЛИ ИХ ВАРИАНТАМИ, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО, И ЕГО ПРИМЕНЕНИЕ
CN101397539B (zh) * 2008-10-14 2011-10-05 中国人民解放军第三军医大学 组织工程组织仿生培养的模拟人体生理应力的施力装置
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
PT3339323T (pt) * 2010-08-12 2020-01-14 Lilly Co Eli Anticorpos anti-péptido beta-amilóide n3pglu e seus usos
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
JP2016501247A (ja) 2012-12-07 2016-01-18 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー 抗Aβ抗体を使用して脳アミロイド斑を減少させる方法
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
SG10201901076WA (en) 2014-02-08 2019-03-28 Genentech Inc Methods of treating alzheimer's disease
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en) * 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
JP6201928B2 (ja) * 2014-08-04 2017-09-27 トヨタ自動車株式会社 車両制御装置
TWI570127B (zh) 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
WO2016053767A1 (en) 2014-09-30 2016-04-07 Merck Sharp & Dohme Corp. Novel crystalline forms of a bace inhibitor, compositions, and their use
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途

Also Published As

Publication number Publication date
CN109415433A (zh) 2019-03-01
JP2021059547A (ja) 2021-04-15
MX2023001299A (es) 2023-02-22
CN114887054A (zh) 2022-08-12
TW202140544A (zh) 2021-11-01
SG11201810371XA (en) 2018-12-28
UA127101C2 (uk) 2023-04-19
KR20230021773A (ko) 2023-02-14
JP7241058B2 (ja) 2023-03-16
US11312763B2 (en) 2022-04-26
RS64386B1 (sr) 2023-08-31
HRP20230861T1 (hr) 2023-11-10
DK3478712T3 (da) 2023-09-04
TWI735600B (zh) 2021-08-11
EP4272828A2 (en) 2023-11-08
TW201811363A (zh) 2018-04-01
FI3478712T3 (fi) 2023-10-02
SI3478712T1 (sl) 2023-10-30
ES2958508T3 (es) 2024-02-09
EP3478712B1 (en) 2023-07-19
ZA201807633B (en) 2021-05-26
JP2023123503A (ja) 2023-09-05
EP4272828A3 (en) 2024-01-10
WO2018005282A1 (en) 2018-01-04
AU2017291414A1 (en) 2018-12-13
CN114917338A (zh) 2022-08-19
TWI798751B (zh) 2023-04-11
MA45543B1 (fr) 2023-08-31
CA3029550C (en) 2023-08-22
KR102221402B1 (ko) 2021-03-02
MA45543A (fr) 2019-05-08
AU2017291414B2 (en) 2019-11-21
JP2019518783A (ja) 2019-07-04
EP3478712A1 (en) 2019-05-08
JP7165588B2 (ja) 2022-11-04
EA201892690A1 (ru) 2019-05-31
US20190382471A1 (en) 2019-12-19
IL263788B1 (en) 2024-06-01
LT3478712T (lt) 2023-08-25
MX2018016066A (es) 2019-04-24
KR20190012208A (ko) 2019-02-08
PL3478712T3 (pl) 2023-11-06
CA3029550A1 (en) 2018-01-04
KR20210024213A (ko) 2021-03-04
US20220235122A1 (en) 2022-07-28
IL263788A (en) 2019-01-31
BR112018073843A2 (pt) 2019-02-26
NZ748496A (en) 2021-02-26
MD3478712T2 (ro) 2024-01-31
JP2021059546A (ja) 2021-04-15
HUE062980T2 (hu) 2023-12-28

Similar Documents

Publication Publication Date Title
ZA202007868B (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
ZA201901207B (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
IL263788A (en) Anti-peptide n3pglu amyloid beta antibodies and their uses
ZA201801943B (en) Anti¿lag3 antibodies and uses thereof
IL262095A (en) Anti-pacap antibodies and their use
IL290783A (en) Anti-tau antibodies and their uses
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
HK1259324A1 (zh) 澱粉樣蛋白β表位及其抗體
HK1259325A1 (zh) 澱粉樣蛋白β中的N-末端表位及其構象選擇性抗體
EP3374380A4 (en) C-TERMINAL EPITOPES IN BETA-AMYLOID AND RELATED CONFORMATIONAL ANTIBODIES
IL262244B1 (en) Antibodies against beta interferon and their use
IL266049A (en) Antibodies against o1 and their uses
EP3374382A4 (en) BETA-AMYLOID EPITOPES AND ASSOCIATED SELECTIVE CONFORMATIONAL ANTIBODIES
IL266082A (en) Anti-chikv antibodies and their use
IL264417A (en) Anti-o2 antibodies and their uses
GB201519105D0 (en) Antibody polypeptides and uses thereof
GB201517550D0 (en) Antibody polypeptides and uses thereof